Mallinckrodt’s Financial Struggles Put Opioid Settlement at Risk
Wall Street Journal
The generic drugmaker is at risk of filing for bankruptcy again, a development that stands to disrupt its commitment to paying opioid victims under a settlement deal—but former executives are likely to keep their liability releases anyway.